ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
The impact of the PI3K/AKT/mTOR signaling pathway on trastuzumab resistance in HER2-positive gastric cancer.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer is a major cause of cancer-related mortality worldwide, frequently diagnosed at advanced stages due to its asymptomatic early course. HER2-positive gastric cancer represents a clinically significant subgroup, characterized by overexpression of the HER2 receptor, which promotes tumor progression and adverse clinical outcomes. Trastuzumab, a monoclonal antibody targeting HER2, has achieved substantial therapeutic advances; however, the emergence of treatment resistance remains a major limitation. Recent evidence indicates that the PI3K/Akt/mTOR signaling pathway plays a central role in mediating trastuzumab resistance, as its dysregulation enhances tumor cell survival and proliferation, angiogenesis, epithelial-to-mesenchymal transition, and evasion of apoptosis, ultimately resulting in treatment failure. This study examines the biological and clinical significance of HER2 in gastric cancer and explores the molecular mechanisms underlying PI3K/Akt/mTOR-mediated resistance to trastuzumab. Furthermore, emerging therapeutic strategies targeting these mechanisms may facilitate the development of effective, personalized treatment approaches for patients with HER2-positive gastric cancer.
Indexed as
Identifiers
42268566What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.